CD8A and neoplasm: In line with this, a recent clinical trial using HCQ and gemcitabine plus nabpaclitaxel (GnP), a standard-of-care chemotherapy for PDAC [102], as neoadjuvant chemotherapy (NCT01978184), showed that the addition of HCQ increased the number of tumor-infiltrating CD8+ T cells [103, 104].